The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology ...
BioDelivery Sciences International Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, has entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.
RALEIGH, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced it expects 2021 total Company net revenues and BELBUCA® (buprenorphine buccal film) net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.
RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.
The U.S. Department of Veteran Affairs has awarded BioDelivery Sciences International (BDSI +4.7%) a five-year contract valued at $24M. The contract …
Belbuca (Buprenorphine) : BioDelivery Sciences International v. Alvogen Pb Research & Development
Endo said the restructuring will better align those parts of its organization with its recently restructured generics and U.S branded pharmaceutical business units. As a result, Endo said the restructuring should generate cost savings between $40 and $50 million per year. Endo said those savings will be invested into the company’s core product franchises, as well as new product development programs in both the branded and generics business segments. Endo’s core drugs include Xiaflex, which is used to treat Dupuytren's contracture in adults, Opana ER and Percocet.
MonoSol Rx, a specialty pharmaceutical company utilizing its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today filed a patent infringement case against BioDelivery Sciences International, Inc. (Nasdaq:BDSI) (“BDSI”) for infringement of U.S. Patent No. 8,765,167 (the ‘167 patent), which is entitled “Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions.” The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005. The complaint was filed in the United States District Court for the District of New Jersey. The complaint asserts that the manufacture, marketing and sale of BDSI’s BELBUCA™ (buprenorphine) buccal film product infringes the ‘167 patent. Specifically, the complaint asserts infringement of claims 13, 33, 39, 45, 52, 66, 73, 83, 89, 95-98, 100-103, 105, 107, 108, 117 and 118 of the ’167 patent (Asserted Claims).
Endo poached Sanofi’s Patrick Barry as the company’s senior vice president of U.S. Branded Pharmaceuticals. Barry will assume his new position immediately, the company said in a statement this morning. Barry will be responsible for all commercial activities for U.S. Branded Pharmaceuticals, including strategy, new product planning, marketing and sales, the company said. Barry served at Sanofi for more than 20 years. His most recent position was general manager and head of North America General Medicines.
BioDelivery Sciences International, Inc. (BDSI) announced that its phase 2b clinical study assessing the efficacy and safety of Clonidine topical gel for the management of painful diabetic neuropathy failed to show a statistically significant difference in pain relief between Clonidine topical gel and placebo. As a result, BDSI is discontinuing further development of the product at this time.